Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23292776 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL921568 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL14767386 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL23292781 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL9558015 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL23292769 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL23292832 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL473472 | 0.97 | — | — | |
| SCHEMBL7752682 | 0.95 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL3427004 | 0.95 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7091357-B2 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
| EP-1315733-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-1187820-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002020531-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001000602-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | CHRNA4, CHRNA2, CHRNA5 | SIGMAR1 152/4885CYP1A2 744/4885KDM5A 2241/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SIGMAR1 234/4885CYP1A2 659/4885KDM5A 4851/4885 |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | SIGMAR1 1608/4885CYP1A2 32/4885KDM5A 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.